Concepts (97)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 | 2022 | 1514 | 1.240 |
Why?
|
| Pneumocystis carinii | 1 | 2020 | 72 | 0.750 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2020 | 246 | 0.690 |
Why?
|
| Opportunistic Infections | 1 | 2020 | 390 | 0.610 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 1370 | 0.460 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2020 | 5412 | 0.340 |
Why?
|
| Pyrazoles | 1 | 2016 | 1957 | 0.290 |
Why?
|
| Neoplasm, Residual | 2 | 2022 | 986 | 0.260 |
Why?
|
| Pyrimidines | 1 | 2016 | 2930 | 0.260 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2016 | 5111 | 0.180 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 814 | 0.170 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 13626 | 0.170 |
Why?
|
| Retreatment | 1 | 2019 | 623 | 0.160 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 1525 | 0.160 |
Why?
|
| Cardiology Service, Hospital | 1 | 2019 | 255 | 0.160 |
Why?
|
| Staurosporine | 3 | 2012 | 254 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2022 | 11236 | 0.150 |
Why?
|
| Chimerism | 1 | 2016 | 151 | 0.140 |
Why?
|
| Lymphocyte Depletion | 1 | 2016 | 635 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 2824 | 0.130 |
Why?
|
| Germinal Center | 1 | 2016 | 373 | 0.120 |
Why?
|
| Lymphoma, B-Cell | 1 | 2019 | 931 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2016 | 529 | 0.110 |
Why?
|
| Withholding Treatment | 1 | 2016 | 587 | 0.110 |
Why?
|
| Patient Admission | 1 | 2019 | 1396 | 0.110 |
Why?
|
| Adenine | 1 | 2016 | 897 | 0.110 |
Why?
|
| Th2 Cells | 1 | 2016 | 1053 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 5198 | 0.100 |
Why?
|
| Urea | 1 | 2012 | 441 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 2789 | 0.090 |
Why?
|
| Piperidines | 1 | 2016 | 1582 | 0.080 |
Why?
|
| Transplantation, Homologous | 1 | 2016 | 4824 | 0.080 |
Why?
|
| Thiophenes | 1 | 2012 | 601 | 0.080 |
Why?
|
| Tissue Donors | 1 | 2016 | 2151 | 0.080 |
Why?
|
| Treatment Outcome | 5 | 2020 | 62004 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 9596 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2016 | 3424 | 0.070 |
Why?
|
| Recurrence | 1 | 2016 | 8240 | 0.070 |
Why?
|
| Graft vs Host Disease | 1 | 2016 | 2804 | 0.060 |
Why?
|
| Protein Kinases | 1 | 2012 | 1665 | 0.060 |
Why?
|
| Camptothecin | 3 | 2012 | 551 | 0.060 |
Why?
|
| African Americans | 1 | 2019 | 5003 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 3035 | 0.060 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 4902 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 5038 | 0.060 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3163 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3280 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 2947 | 0.050 |
Why?
|
| Genes, p53 | 2 | 2012 | 764 | 0.050 |
Why?
|
| Humans | 10 | 2022 | 715777 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 3741 | 0.040 |
Why?
|
| Neoplasms | 2 | 2021 | 20528 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2022 | 51315 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2020 | 630 | 0.040 |
Why?
|
| Heart Failure | 1 | 2019 | 10041 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2012 | 20062 | 0.030 |
Why?
|
| Aged | 5 | 2020 | 162448 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2016 | 40029 | 0.030 |
Why?
|
| Ribosomal Protein S6 | 1 | 2012 | 71 | 0.030 |
Why?
|
| Middle Aged | 5 | 2020 | 214639 | 0.030 |
Why?
|
| Genes, cdc | 1 | 2012 | 125 | 0.030 |
Why?
|
| Genes, erbB-2 | 1 | 2012 | 166 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 1785 | 0.020 |
Why?
|
| Adult | 4 | 2020 | 212266 | 0.020 |
Why?
|
| Female | 6 | 2020 | 377204 | 0.020 |
Why?
|
| Inpatients | 1 | 2019 | 2255 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 618 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2020 | 2802 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 903 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2019 | 1738 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2012 | 1904 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2012 | 1118 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2020 | 10499 | 0.020 |
Why?
|
| Male | 4 | 2020 | 350324 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 1773 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 2787 | 0.020 |
Why?
|
| Boston | 1 | 2019 | 9377 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 1726 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2021 | 13213 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2019 | 2980 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 58323 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 2167 | 0.020 |
Why?
|
| Anemia | 1 | 2012 | 1419 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 3633 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2012 | 2993 | 0.020 |
Why?
|
| DNA Damage | 1 | 2012 | 2434 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 7311 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2019 | 23464 | 0.010 |
Why?
|
| Time Factors | 1 | 2019 | 40875 | 0.010 |
Why?
|
| Apoptosis | 1 | 2012 | 9973 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 16736 | 0.010 |
Why?
|
| Risk Factors | 1 | 2019 | 70866 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2019 | 72443 | 0.010 |
Why?
|
| Mutation | 1 | 2012 | 29291 | 0.010 |
Why?
|
| Mice | 1 | 2012 | 80375 | 0.000 |
Why?
|
| Young Adult | 1 | 2010 | 56226 | 0.000 |
Why?
|
| Animals | 1 | 2012 | 169420 | 0.000 |
Why?
|
Concepts
(97)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(74)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_